Compare drug alternatives
Segluromet® Alternatives
Segluromet®(Ertugliflozin And Metformin Hydrochloride) | Trijardy XR®(Empagliflozin, Linagliptin, Metformin Hydrochloride) |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | Dosage & Administration comparison data |
Administration | |
Oral . Learn more. | Oral . Learn more. |
Dosing | |
Maximum recommended dose is 7.5 mg ertugliflozin/1,000 mg metformin twice daily. Take twice daily with meals, with gradual dose escalation. Do not use in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m2 . . Learn more. | The maximum recommended dose of TRIJARDY XR is 25 mg empagliflozin, 5 mg linagliptin and 2000 mg metformin HCl. Take once daily with a meal in the morning. Swallow whole; do not split, crush, dissolve, or chew.. Learn more. |
Latin Shorthand | |
Max dose: 7.5 mg ertugliflozin / 1000 mg metformin BID. Take with meals, gradual dose increase. Avoid if eGFR < 30 mL/min/1.73 m².. Learn more. | Max dose TRIJARDY XR: 25 mg empagliflozin, 5 mg linagliptin, 2000 mg metformin HCl. Take 1x daily with AM meal. Swallow whole; no splitting, crushing, dissolving, or chewing.. Learn more. |
| Financial Assistance | Financial Assistance comparison data |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | $10. Learn more. |
Annual Cap | |
$583 per fill . Learn more. | $175 per month. Learn more. |
Assistance Expiration | |
12 uses. Learn more. | 12/31/23. Learn more. |
Generics | |
No lower-cost generic available | No lower-cost generic available |
| Physician Advisory | Physician Advisory comparison data |
Adverse Reactions | |
Most common adverse reactions associated with ertugliflozin
(incidence ≥5%) were female genital mycotic infections.
Most common adverse reactions associated with metformin
(incidence ≥5%) were diarrhea, nausea, vomiting, flatulence,
abdominal discomfort, indigestion, asthenia, and headache. . Learn more. | Most common adverse reactions (5% or greater incidence) were upper
respiratory tract infection, urinary tract infection, nasopharyngitis, diarrhea,
constipation, headache, and gastroenteritis. . Learn more. |
Mechanism of Actions (MoA) | |
SGLT2 Inhibitors. Learn more. | SGLT2 Inhibitors. Learn more. |
Special Populations | |